GENE ONLINE|News &
ASGCT21 Highlights: Present Trends and Future Directions of Gene and Cell Therapies in Immuno-Oncology
During the virtual ASGCT meeting, experts reflected on the current trends and future directions of gene and cell therapies in immuno-oncology.
Engineering T Cells to Better Recognize Cancer Cells
Current immune checkpoint therapies try to release the breaks of the T cells to fight cancer. Most of these therapies target either CTLA-4, which prevents T cell activation at the lymph nodes or PD-1/PD-L1, which downregulates T cell activity in the tumor microenvironment.
Engineering T Cells to Better Recognize Cancer Cells
Current immune checkpoint therapies try to release the breaks of the T cells to fight cancer. Most of these therapies target either CTLA-4, which prevents T cell activation at the lymph nodes or PD-1/PD-L1, which downregulates T cell activity in the tumor microenvironment.
